IRVINE, Calif., April 28, 2006 (PRIMEZONE) -- "Companies developing drugs and treatments within the cancer field are showcasing their findings with public presentations to the most important of audiences," stated SmallCap Sentinel analyst D.R. Clark. "It's a critical part of the treatment development process for companies to bring their candidates to the scientific community."
"Last week, Callisto Pharmaceuticals, Inc. (AMEX:KAL), a developer of new drug treatments in the fight against cancer, announced that four abstracts on the company's Degrasyn class of drug candidates were subjects of poster presentations at the American Association of Cancer Research (AACR) meeting in Washington D.C.," Clark added. "This is a leading scientific conference in the field of cancer research and an enormous step for Callisto to bring their scientific progress to this critical audience."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address a variety of biotech and pharmaceutical related issues for companies including Merck (NYSE:MRK), Pfizer (NYSE:PFE), Glaxosmithkline PLC (NYSE:GSK), and Callisto Pharmaceuticals (AMEX:KAL).
Callisto Pharmaceuticals is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and advanced carcinoid cancer. Callisto also has drugs in pre-clinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus.
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: www.trilogy-capital.com/kal_summary.aspx
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable, but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor offer to sell securities, but is rather a paid advertisement provided for information purposes only, and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.